PPD: A $16 Billion Clinical Research BusinessNarrow moat

Thermo Fisher Scientific (TMO) — moat facet

Buying PPD for $16 billion made Thermo Fisher a clinical trial company, and the trial business has grown about 1% a year since.

Thermo Fisher became a clinical research company in December 2021, when it bought PPD. The booked price was $16,036 million net of cash, plus $4,299 million of debt assumed1. Goodwill from the purchase was $13,781 million and the backlog was valued as an intangible asset at $1,060 million2.

PPD purchase price allocation, December 2021 ($M)13,781Goodwill1,060Backlog intangible4,299Debt assumed16,036Price net of cashThermo Fisher Form 10-K FY2021
Most of the price was goodwill.

The purchase changed what kind of company this is. Headcount was more than 80,000 at the end of 20203 and approximately 130,000 a year later4. Service revenue went from $8,850 million in 2021 to $16,367 million in 20225.

Clinical research revenue has been steady since: $7,691 million in 2023, $7,836 million in 2024 and $7,915 million in 20256. IQVIA, a rival, names PPD in its own 10-K as one of its larger competitors7.

The moat here is relationships and a record. Drug companies hand a trial to a contractor they trust with their regulatory submission, and changing contractors mid-programme is costly.

Headcount shows the integration. It was approximately 130,000 at the end of 20218, just after PPD, and approximately 122,000 at the end of 20239, as the company cut costs across the combined business. It was approximately 125,000 at the end of 202510, of whom about 59,000 were in the Americas11.

This facet is narrow because growth has been slow. It would be falsified by clinical research revenue falling, before acquisitions, for a full year. Excluding Clario, 2026 revenue near 2025's $7,915 million would mean PPD has stopped growing.

Moat trajectory: Holding steady

Clinical research $7,691M (2023) to $7,915M (2025).

The number that tests this moat
Reported
Employees, year end
Approximately 125,000 (2025), from more than 80,000 (2020)

The labour the services business needs; growth faster than revenue would mean the trials are getting less profitable.

Source: Thermo Fisher Form 10-K, FY2025 ↗
⚠ Threats to the moat
⚠ THREAT 01
Clinical Research Grew 1.0% in 2025
Thermo Fisher's $16 billion clinical research business grew 1.0% in 2025, before Clario was added.
References
  1. ReportedThe booked price was $16,036 million net of cash, plus $4,299 million of debt assumed.
    Thermo Fisher Scientific Form 10-K for fiscal 2021 - the PPD, PeproTech, Brammer Bio, European viral vector and Mesa Biotech acquisitions, the Anatomical Pathology sale, COVID-19 response revenue, headcount and remaining performance obligations. — FY2021 · publ. February 2022 · source ↗
  2. ReportedGoodwill from the purchase was $13,781 million and the backlog was valued as an intangible asset at $1,060 million.
    Thermo Fisher Scientific Form 10-K for fiscal 2021 - the PPD, PeproTech, Brammer Bio, European viral vector and Mesa Biotech acquisitions, the Anatomical Pathology sale, COVID-19 response revenue, headcount and remaining performance obligations. — FY2021 · publ. February 2022 · source ↗
  3. ReportedHeadcount was more than 80,000 at the end of 2020 and approximately 130,000 a year later.
    Thermo Fisher Scientific Form 10-K for fiscal 2020 - segment revenue for 2018-2020, revenue by type and geography, COVID-19 revenue, headcount and remaining performance obligations. — FY2020 · publ. February 2021 · source ↗
  4. ReportedHeadcount was more than 80,000 at the end of 2020 and approximately 130,000 a year later.
    Thermo Fisher Scientific Form 10-K for fiscal 2021 - the PPD, PeproTech, Brammer Bio, European viral vector and Mesa Biotech acquisitions, the Anatomical Pathology sale, COVID-19 response revenue, headcount and remaining performance obligations. — FY2021 · publ. February 2022 · source ↗
  5. ReportedService revenue went from $8,850 million in 2021 to $16,367 million in 2022.
    Thermo Fisher Scientific Form 10-K for fiscal 2022 - segment revenue and income for 2020-2022, revenue by type and by geography including China, and COVID-19 testing revenue. — FY2022 · publ. February 2023 · source ↗
  6. ReportedClinical research revenue has been steady since: $7,691 million in 2023, $7,836 million in 2024 and $7,915 million in 2025.
    Thermo Fisher Scientific Form 10-K for fiscal 2025 - revenue by business. — FY2025 · publ. 26 February 2026 · source ↗
  7. ReportedIQVIA, a rival, names PPD in its own 10-K as one of its larger competitors.
    IQVIA Holdings Form 10-K for fiscal 2025 - names ICON, Parexel, Pharmaceutical Product Development (part of Thermo Fisher Scientific) and Syneos Health among its larger competitors. — FY2025 · publ. February 2026 · source ↗
  8. ReportedIt was approximately 130,000 at the end of 2021, just after PPD, and approximately 122,000 at the end of 2023, as the company cut costs across the combined business.
    Thermo Fisher Scientific Form 10-K for fiscal 2021 - the PPD, PeproTech, Brammer Bio, European viral vector and Mesa Biotech acquisitions, the Anatomical Pathology sale, COVID-19 response revenue, headcount and remaining performance obligations. — FY2021 · publ. February 2022 · source ↗
  9. ReportedIt was approximately 130,000 at the end of 2021, just after PPD, and approximately 122,000 at the end of 2023, as the company cut costs across the combined business.
    Thermo Fisher Scientific Form 10-K for fiscal 2023 - segment revenue and income for 2021-2023, COVID-19 testing revenue, remaining performance obligations, the geographic table without a China line, and the Binding Site and CorEvitas acquisitions. — FY2023 · publ. February 2024 · source ↗
  10. ReportedIt was approximately 125,000 at the end of 2025, of whom about 59,000 were in the Americas.
    Thermo Fisher Scientific Form 10-K for fiscal 2025 - financial statements: income, cash flow, repurchases, debt and equity. — FY2025 · publ. 26 February 2026 · source ↗
  11. ReportedIt was approximately 125,000 at the end of 2025, of whom about 59,000 were in the Americas.
    Thermo Fisher Scientific Form 10-K for fiscal 2025 - financial statements: income, cash flow, repurchases, debt and equity. — FY2025 · publ. 26 February 2026 · source ↗
Sources
Generated September 28, 2026